AIM: To investigate the therapeutic efficacy and mechanisms of action of oncolytic-herpes-simplex-virus encoding granulocyte-macrophage colony-stimulating factor (HSV(GM-CSF)) in pancreatic carcinoma. METHODS: Tumor blocks were homogenized in a sterile grinder in saline. The homogenate was injected into the right armpit of each mouse. After vaccination, the mice were randomly assigned into four groups: a control group, a high dose HSV(GM-CSF) group [1 × 10⁷ plaque forming units (pfu)/tumor], a medium dose HSV(GM-CSF) group (5 × 10⁶ pfu/tumor) and a low dose HSV(GM-CSF) group (5 × 10⁵ pfu/tumor). After initiation of drug administration, body weights and tumor diameters were measured every 3 d. Fifteen days later, after decapitation of the animal by cervical dislocation, each tumor was isolated, weighed and stored in 10% formaldehyde solution. The drug effectiveness was evaluated according to the weight, volume and relative volume change of each tumor. Furthermore, GM-CSF protein levels in serum were assayed by enzyme-linked immunosorbent assays at 1, 2, 3 and 4 d after injection of HSV(GM-CSF). RESULTS: Injection of the recombinant mouse HSV encoding GM-CSF resulted in a significant reduction in tumor growth compared to the control group, and dose-dependent effects were observed: the relative tumor proliferation rates of the low dose, medium dose and high dose groups on 15 d after injection were 45.5%, 55.2% and 65.5%, respectively. The inhibition rates of the tumor weights of the low, middle, and high dose groups were 41.4%, 46.7% and 50.5%, respectively. Furthermore, the production of GM-CSF was significantly increased in the mice infected with HSV(GM-CSF). The increase in the GM-CSF level was more pronounced in the high dose group compared to the other two dose groups. CONCLUSION: Our study provides the first evidence that HSV(GM-CSF) could inhibit the growth of pancreatic cancer. The enhanced GM-CSF expression might be responsible for the phenomenon.
AIM: To investigate the therapeutic efficacy and mechanisms of action of oncolytic-herpes-simplex-virus encoding granulocyte-macrophage colony-stimulating factor (HSV(GM-CSF)) in pancreatic carcinoma. METHODS:Tumor blocks were homogenized in a sterile grinder in saline. The homogenate was injected into the right armpit of each mouse. After vaccination, the mice were randomly assigned into four groups: a control group, a high dose HSV(GM-CSF) group [1 × 10⁷ plaque forming units (pfu)/tumor], a medium dose HSV(GM-CSF) group (5 × 10⁶ pfu/tumor) and a low dose HSV(GM-CSF) group (5 × 10⁵ pfu/tumor). After initiation of drug administration, body weights and tumor diameters were measured every 3 d. Fifteen days later, after decapitation of the animal by cervical dislocation, each tumor was isolated, weighed and stored in 10% formaldehyde solution. The drug effectiveness was evaluated according to the weight, volume and relative volume change of each tumor. Furthermore, GM-CSF protein levels in serum were assayed by enzyme-linked immunosorbent assays at 1, 2, 3 and 4 d after injection of HSV(GM-CSF). RESULTS: Injection of the recombinant mouse HSV encoding GM-CSF resulted in a significant reduction in tumor growth compared to the control group, and dose-dependent effects were observed: the relative tumor proliferation rates of the low dose, medium dose and high dose groups on 15 d after injection were 45.5%, 55.2% and 65.5%, respectively. The inhibition rates of the tumor weights of the low, middle, and high dose groups were 41.4%, 46.7% and 50.5%, respectively. Furthermore, the production of GM-CSF was significantly increased in the mice infected with HSV(GM-CSF). The increase in the GM-CSF level was more pronounced in the high dose group compared to the other two dose groups. CONCLUSION: Our study provides the first evidence that HSV(GM-CSF) could inhibit the growth of pancreatic cancer. The enhanced GM-CSF expression might be responsible for the phenomenon.
Authors: Kevin J Harrington; Mohan Hingorani; Mary Anne Tanay; Jennifer Hickey; Shreerang A Bhide; Peter M Clarke; Louise C Renouf; Khin Thway; Amen Sibtain; Iain A McNeish; Kate L Newbold; Howard Goldsweig; Robert Coffin; Christopher M Nutting Journal: Clin Cancer Res Date: 2010-08-01 Impact factor: 12.531
Authors: Sunil K Geevarghese; David A Geller; Hans A de Haan; Markus Hörer; Anette E Knoll; Axel Mescheder; John Nemunaitis; Tony R Reid; Daniel Y Sze; Kenneth K Tanabe; Hoda Tawfik Journal: Hum Gene Ther Date: 2010-09 Impact factor: 5.695
Authors: Sandeep Malhotra; Teresa Kim; Jonathan Zager; Joseph Bennett; Michael Ebright; Michael D'Angelica; Yuman Fong Journal: Surgery Date: 2007-02-14 Impact factor: 3.982
Authors: B G Derubertis; B M Stiles; A Bhargava; N J Gusani; M Hezel; M D'Angelica; Y Fong Journal: Cancer Gene Ther Date: 2007-04-13 Impact factor: 5.987
Authors: Cristina R Ferrone; Murray F Brennan; Mithat Gonen; Daniel G Coit; Yuman Fong; Sun Chung; Laura Tang; David Klimstra; Peter J Allen Journal: J Gastrointest Surg Date: 2007-11-20 Impact factor: 3.452
Authors: B J Passer; P Castelo-Branco; J S Buhrman; S Varghese; S D Rabkin; R L Martuza Journal: Cancer Gene Ther Date: 2009-02-06 Impact factor: 5.987
Authors: Nicholas L Denton; Chun-Yu Chen; Brian Hutzen; Mark A Currier; Thomas Scott; Brooke Nartker; Jennifer L Leddon; Pin-Yi Wang; Rachelle Srinivas; Kevin A Cassady; William F Goins; Timothy P Cripe Journal: Mol Ther Oncolytics Date: 2018-10-18 Impact factor: 7.200